PHI with Chronic yellow liver atrophy
How does this condition affect your private health insurance?
Chronic yellow liver atrophy, or "Leberatrophie chronisch gelbe," is an archaic term describing severe, progressive liver disease characterized by chronic jaundice and significant shrinkage (atrophy) of the liver. This condition typically represents the end-stage of various chronic liver insults, such as long-standing viral hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), or autoimmune liver diseases. It results in widespread destruction of liver cells, fibrosis, and impaired liver function, leading to symptoms like profound fatigue, ascites, encephalopathy, bleeding tendencies, and intractable jaundice. The liver's ability to detoxify, synthesize essential proteins, and metabolize bilirubin is severely compromised, culminating in chronic liver failure.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to months for acute decompensation, often preceded by years of milder symptoms.
Duration of Illness (Lifetime)
Chronic disease, potentially lasting years, often progressive until liver failure or transplantation.
Cost of Treatment (Initial)
High (tens of thousands to hundreds of thousands USD for initial hospitalization and stabilization).
Cost of Treatment (Lifetime)
Very high (hundreds of thousands to over a million USD, especially if liver transplantation is required).
Mortality Rate
High, exceeding 50% within a few years without transplantation for end-stage disease.
Risk of Secondary Damages
Very high (e.g., hepatic encephalopathy, ascites, variceal bleeding, hepatorenal syndrome, increased infection risk).
Probability of Full Recovery
Very low for complete recovery of native liver function; often requires liver transplantation for survival.
Underlying Disease Risk
High probability of underlying chronic liver diseases such as viral hepatitis (B or C), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD)/NASH, or autoimmune liver diseases.